Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,765 signal articles · 246 in last 24h · 118,039 total before filter · latest 1h ago
246last 24h
1610last 7d
250● bullish (7d)
159● bearish (7d)
205publishers
AllMacro306Earnings675M&A92Regulatory28Product13Analyst24
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales
StockStory12d agobullish
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.

Investing.com12d agoneutral
Atlassian rockets 23% after crushing earnings and flexing cloud & AI muscle

The company posted adjusted earnings per share of $1.87, beating the analyst consensus of $1.50 by $0.37. Revenue reached $1.77 billion, surpassing the $1.66 billion estimate and representing a 28% increase YoY from $1.38 billion in the same quarter last year. Cloud revenue grew 31% YoY to $1.21 billion, while Data Center revenue came in at $461.9 million, above the $414.6 million estimate.

Shares of Memory Giants Drop on Soft Guidance
The Wall Street Journal12d agobearish
Shares of Memory Giants Drop on Soft Guidance

Shares of AI darlings Western Digital and Sandisk fell. Sandisk’s forward guidance was slightly below previous analyst estimates, while Western Digital’s outlook was in-line with expectations. Western Digital declined 13%, while Sandisk dropped 7%.

Airbnb raises 2026 outlook after Q2 earnings top estimates
Proactive12d agoneutral
Airbnb raises 2026 outlook after Q2 earnings top estimates

Airbnb Inc (NASDAQ:ABNB, XETRA:6Z1) shares rose about 10% after Thursday’s closing bell after the alternative accommodation provider reported better-than-expected second quarter results and raised its full-year revenue and adjusted EBITDA margin guidance, citing continued strong travel...

Airbnb Raises Guidance After Second-Quarter Earnings Beat
Barrons.com12d agobullish
Airbnb Raises Guidance After Second-Quarter Earnings Beat

Vacation rental site Airbnb beat second-quarter earnings expectations and again raised its full-year outlook, crediting an accelerated pace of bookings and continued strong travel demand despite higher costs. Airbnb shares were up more than 11% in after hours trading, after closing down 0.6% at $151.64 in regular trading. Airbnb said it delivered some of the strongest results in years during the first half of 2026, and that it exceeded its outlook across every key metric for the second quarter.

Block (XYZ) Stock May Be 14% Undervalued On Q2 Earnings Beat
Simply Wall St.12d agobullish
Block (XYZ) Stock May Be 14% Undervalued On Q2 Earnings Beat

Block stock has delivered a steep 68.9% decline over the past five years, yet the current checks send mixed messages on value, with the Excess Returns intrinsic value estimate suggesting upside while earnings based multiples lean expensive. The share price performance over five years is down 68.9%, which puts a spotlight on whether the current level reflects a reset opportunity or lingering concerns. Recent growth in Cash App and Square activity can support higher earnings expectations,...

JPMorgan resets SpaceX price target after earnings
TheStreet12d agoneutral
JPMorgan resets SpaceX price target after earnings

Wall Street had a simple question heading into SpaceX's first earnings report as a public company. Was the spending worth it? The answer came in the form of a single number that landed on Aug. 4 and immediately changed the tone of every conversation about the stock. The stock had been trading near ...

Iovance Biotherapeutics Q2 Earnings Call Highlights
MarketBeat12d agoneutral
Iovance Biotherapeutics Q2 Earnings Call Highlights

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic

Honeywell (HON) Completes Aerospace Spin Off As Standalone Guidance Takes Shape
Simply Wall St.12d agoneutral
Honeywell (HON) Completes Aerospace Spin Off As Standalone Guidance Takes Shape

Honeywell Aerospace, recently spun off from Honeywell International (NasdaqGS:HON), reported its first standalone financial results and issued new guidance. The newly independent aerospace company outlined its operating strategy, including capital allocation plans and priorities for future contract opportunities. Management highlighted recent contract wins and provided an update on the order pipeline as part of its initial outlook to investors. Consider reviewing other established dividend...

On Holding (NYSE:ONON) Stock May Trade At A Premium Following Earnings Next Week
Simply Wall St.12d agoneutral
On Holding (NYSE:ONON) Stock May Trade At A Premium Following Earnings Next Week

On Holding stock has fallen 18.7% year to date, yet its Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market multiples suggest the shares are priced on the rich side. With earnings news approaching and a low overall value score, investors are weighing a discounted cash flow signal against a less generous read from traditional ratios. On Holding is down 18.7% so far in 2026, which puts extra focus on whether the current price offers a margin of safety...

Immunovant Q1 Earnings Call Highlights
MarketBeat12d agoneutral
Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt

Himax Technologies Q2 Earnings Call Highlights
MarketBeat12d agoneutral
Himax Technologies Q2 Earnings Call Highlights

Himax Technologies (NASDAQ:HIMX) reported second-quarter 2026 results that exceeded its prior guidance, as stronger-than-expected automotive integrated-circuit sales lifted revenue, gross margin and profit. Revenue for the quarter totaled $227.4 million, up 14.2% sequentially and 5.9% from a year e